Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ayumi to Leverage IT to Boost Sales and Marketing, Eyes More Licensing Deals
July 2, 2021
- Towa Now Curbs Shipments for 235 Products; 27 Added to Restriction List
July 2, 2021
- Kaken Grants European Rights for Efinaconazole to Almirall
July 2, 2021
- Mitsubishi Tanabe Rolls Out Oral Film ALS Drug in US
July 2, 2021
- Ex-BMS Exec Tsuji Takes Reins of Mundipharma Japan
July 2, 2021
- Solasia Files NDA for PTCL Drug in Japan
July 2, 2021
- Shionogi’s Chinese JV Commences RWD Collection, Analysis of Metabolic Diseases
July 2, 2021
- Takeda Revises Rules to Enable Fully Virtual Shareholders Meetings
July 1, 2021
- Nichi-Iko Expects Shipment Controls to Linger beyond April Next Year for 110 Products
July 1, 2021
- Eisai’s Sleep Inducer Dayvigo Now Available in Hong Kong
July 1, 2021
- AbbVie Japan Files Rinvoq for Ankylosing Spondylitis
July 1, 2021
- Taisho Grants Worldwide Rights for Antidepressant TS-121 to US Firm
July 1, 2021
- New BMS Japan Boots Up with Richer Cancer Assets as Celgene Merger Closes
July 1, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
- Japan Top Court Rejects Prosecutors’ Appeal in Diovan Case; Novartis Not Guilty
June 30, 2021
- Takeda CEO Takes Home 1.87 Billion Yen in FY2020
June 30, 2021
- Takeda’s Leuplin Supply Curb Remains More than 1 Year after Measure Set Off
June 29, 2021
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- HIF-PH Med Roxadustat Gets EU Panel Backing: Astellas/FibroGen
June 29, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…